What is OptimizeRx's stock-based comp?

OptimizeRx (OPRX) reported stock-based comp of $1.83M in Q1 2026.

How has OptimizeRx's stock-based comp changed year-over-year?

OptimizeRx's stock-based comp increased by 17.3% year-over-year, from $1.56M to $1.83M.

What is the long-term trend for OptimizeRx's stock-based comp?

Over 4 years (2021 to 2025), OptimizeRx's stock-based comp has grown at a 6.1% compound annual growth rate (CAGR), from $5.49M to $6.96M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

OptimizeRx OPRX Stock-Based Comp

Stock-Based Comp at other companies

Spok HoldingsSPOK

$1.47M+15.8%

Veeva SystemsVEEV

$119.26M+6.3%

PhreesiaPHR

$13.55M-21.3%

DoximityDOCS

$36.74M+103%

GoodRx Holdings, Inc.GDRX

$16.51M-13.9%

PubMaticPUBM

$8.49M-12.5%

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-50.4%

Enterprise value$110.88M-51.4%

P/E15.7×—

P/S1×-1.1×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's stock-based comp?: OptimizeRx (OPRX) reported stock-based comp of $1.83M in Q1 2026.
How has OptimizeRx's stock-based comp changed year-over-year?: OptimizeRx's stock-based comp increased by 17.3% year-over-year, from $1.56M to $1.83M.
What is the long-term trend for OptimizeRx's stock-based comp?: Over 4 years (2021 to 2025), OptimizeRx's stock-based comp has grown at a 6.1% compound annual growth rate (CAGR), from $5.49M to $6.96M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.